$AMGN Company News Nasdaq breaks out, reaches

New Post Public Reply Private Reply Replies (0) Message Board

Aug 21, 2014 at 11:49 AM

$AMGN Company News

Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang

Lilly psoriasis mAb successful in Phase 3 trial 30 min ago - Seeking Alpha
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog 4:27 p.m. Aug. 20, 2014 - Zacks.com
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog 11:08 a.m. Aug. 20, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: AXP, AMGN, USB 10:29 a.m. Aug. 20, 2014 - TheStreet.com
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog 5:25 p.m. Aug. 19, 2014 - Zacks.com
Right on Target 1:33 p.m. Aug. 19, 2014 - Barrons.com
3 Stocks Pulling The Health Care Sector Downward 1:03 p.m. Aug. 19, 2014 - TheStreet.com
Amgen's thyroid drug meets Phase 3 endpoints 5:51 p.m. Aug. 18, 2014 - Seeking Alpha
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog 5:10 p.m. Aug. 18, 2014 - Zacks.com
Amgen (AMGN) Hits New Lifetime High Today 9:45 a.m. Aug. 18, 2014 - TheStreet.com
RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now 8:27 a.m. Aug. 18, 2014 - 247WallSt.com
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen 7:22 a.m. Aug. 15, 2014 - TheStreet.com
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog 5:20 p.m. Aug. 14, 2014 - Zacks.com
Today's Market: Biotech And Technology Names Moving On News 1:33 p.m. Aug. 14, 2014 - Seeking Alpha
Trade-Ideas: Amgen (AMGN) Is Today's "Barbarian At The Gate" Stock 11:17 a.m. Aug. 14, 2014 - TheStreet.com
Amgen Cancer Drug Kyprolis Fails Trial 6:31 p.m. Aug. 13, 2014 - The Wall Street Journal Interactive Edition
Amgen cancer drug fails Phase 3 trial 5:54 p.m. Aug. 13, 2014 - Seeking Alpha
Amgen recalls certain lots of Aranesp 5:38 p.m. Aug. 13, 2014 - Seeking Alpha
After-Hours Trading Shows Amgen (AMGN) Lagging 4:18 p.m. Aug. 13, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: CAT, BIIB, AMGN 10:29 a.m. Aug. 13, 2014 - TheStreet.com

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
A New Cannabinoid-based Arthritis Therapy in the Making 9:50 a.m. Aug. 19, 2014 - ACCESSWIRE
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 1:55 a.m. Aug. 19, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 5:17 p.m. Aug. 18, 2014 - PR Newswire - PRF
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy 9:15 a.m. Aug. 14, 2014 - PR Newswire - PRF
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates 4:12 p.m. Aug. 13, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma 4:01 p.m. Aug. 13, 2014 - PR Newswire - PRF
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs 1:07 p.m. Aug. 11, 2014 - PR Newswire - PRF
Amgen Receives CEO Cancer Gold Standard Accreditation 7:00 a.m. Aug. 11, 2014 - BusinessWire - BZX
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth 9:13 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 11:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
Earnings Headlines - Amgen 9:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint 7:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
RBCC 3D Bioprinting Partner Awarded Prestigious Grant 6:54 a.m. July 31, 2014 - BusinessWire - BZX
Resilinc Named 2014 Great Supply Chain Partner by SupplyChainBrain 10:00 a.m. July 30, 2014 - Marketwire
Global Women%s Health Market 2014-2018 6:20 p.m. July 28, 2014 - PR Newswire - PRF
Amgen Announces 2014 Third Quarter Dividend 4:00 p.m. July 25, 2014 - PR Newswire - PRF
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer 2:30 a.m. July 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allegiant Overhauls Service with UNLV Training

Allegiant Airlines and UNLV: A Unique Collaboration The world of airline customer service is about to get a shakeup, thanks to a new collaboration between Allegiant Airlines and the University of Nevada, Las Vegas' renowned William F. Harrah College of Hospitality. It's a partnership that aims to bring a new level of service to the skies, guided by some of the best minds...

Boosting Heating Efficiency in Aging Massillon Homes

Tackling the Age-Old Heating Puzzle Ah, the charm of an older home—from the creaky floors to the vintage architecture, it's something else. But, let's face it, keeping these houses warm can feel like patching up an old ship. Our man Reid Sittler, HVAC aficionado from Massillon, Ohio, shares some no-nonsense insights on how to stop your precious heat from slipping...

TriMas Streamlines Portfolio with Rapak Sale

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Investigation Looms Over ADT, Instacart, Ultralife Deals

Corporate Deals Under the Microscope: What's at Stake? The headlines are shouting: ADT, Instacart, and Ultralife are all embroiled in merger activities that might not exactly be what shareholders signed up for. On the surface, you've got big names like DoorDash stepping up to snag some of these firms, but the question here is whether the deals are truly fair—or if...

Lazard Closes Deal with Campbell, Launches Lazard CL

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

PG&E's $2B Delay: A Blame Game or Real Crisis?

Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...

Skanska's Bold CZK 2.2B Prague Venture: What's Brewing?

Skanska Rolls the Dice with CZK 2.2 Billion We got Skanska pushing forward with a beefy CZK 2.2 billion investment, translating to about SEK 1 billion, into a new residential phase right in the heart of Prague. It's part of the grand Emil Kolben District project, tasked with blending modern living with low-energy savvy in a city that's slowly shrugging off its industrial...

New Study Exposes Grim Reality for Moderate Aortic Stenosis

Uncovering the Stark Truth of Moderate Aortic Stenosis When you hear about heart issues, the last thing you want to think about is moderate anything. But this study out of San Diego sure throws a wrench in how we size up moderate aortic stenosis. Turns out these patients aren't just in a holding pattern—they're facing some serious storm clouds. High Stakes for...

Envision's 800V DC System Cuts the Powercake First

Envision Hits a Milestone in AI Power Dynamics You ever feel like the future is knocking on your door, but you've still got your headphones on? Well, Envision just kicked the door open with the world's first commercial deployment of an integrated 800-volt direct current (800V DC) power system in a large-scale AI data center. This technological marvel is now up and running...

ELEGOO Slashes Prices up to 54% for 2026 Holiday Deals

ELEGOO's 2026 Holiday Strategy: Deep Discounts Welcome to the world of sharp deals and crafty creations as ELEGOO kicks off its Black Friday and Cyber Monday extravaganza. This time, they're slashing prices by up to 54% on their impressive lineup of 3D printers and captivating accessories. Yeah, it's that time of year when wallets might take a hit, but for a good reason....